BURLINGTON, Mass. — March 4, 2026 — Leads & Copy —
BrainsWay Ltd. (NASDAQ & TASE: BWAY) has announced new clinical data showcasing a faster, noninvasive method for treating depression without compromising the effectiveness of current psychiatric treatments. The data supports BrainsWay’s brain health vision and its neuromodulation platform.
Two peer-reviewed manuscripts in Brain Stimulation revealed that BrainsWay’s SWIFT™ accelerated Deep Transcranial Magnetic Stimulation (Deep TMS™) protocol for Major Depressive Disorder (MDD) achieved similar remission and response rates compared to the traditional protocol. The accelerated protocol reduces the acute treatment phase to six half-days, followed by weekly maintenance visits for four weeks, a significant reduction from the traditional 20 visits.
According to BrainsWay, the SWIFT approach could change interventional psychiatry by reducing clinic visits by about 70% during the acute phase, which could improve patient retention and expand clinical options amid rising demand for non-drug depression therapies.
In a large, randomized, multisite non-inferiority trial, patients treated with BrainsWay’s accelerated protocol achieved an 87.8% response rate and a 78.0% remission rate. The median time to remission was 21 days, compared to 28 days under the standard protocol.
Colleen A. Hanlon, Ph.D., Vice President of Medical Affairs at BrainsWay, said that SWIFT demonstrates the ability to substantially reduce treatment burden without compromising outcomes, which changes what access looks like for patients.
Over 20 million U.S. adults live with MDD, creating an estimated $333 billion annual economic burden. Logistical barriers such as time away from work, caregiving responsibilities, and travel reduce the number of people who start treatment. SWIFT™ seeks to lower these barriers by reducing the amount of time needed for treatment.
The second published manuscript highlighted the human impact of this efficiency, focusing on patients’ ratings of how the treatment affected their lives. Approximately 70% of participants no longer suffered from severe quality of life impairment, and about 60% returned to normal-range functioning after treatment.
Patients also reported earlier symptom improvement across various measures, consistent with clinician-rated outcomes. Hanlon said that patients are reconnecting with work, relationships, and routines and that is the human outcome that matters most.
Evernorth® Behavioral Health has also reduced administrative barriers by eliminating prior authorization requirements for Deep TMS.
BrainsWay Chief Executive Officer Hadar Levy stated that innovation in mental health must address accessibility and scalability, in addition to clinical efficacy. Levy believes that SWIFT demonstrates that neuroscience can be advanced while expanding real-world reach.
The trial incorporated input from both patients and providers in urban and rural areas. The accelerated SWIFT protocol achieved an 87.8% response rate and a 78.0% remission rate on the clinician-rated Hamilton Depression Rating Scale (HDRS-21). The standard protocol consists of an acute phase of five daily sessions over four weeks, followed by two daily sessions per week for two weeks. Outcomes were consistent across diverse patient subgroups, including individuals with moderate-to-severe depression and comorbid anxiety symptoms.
Daily patient assessments confirmed substantial improvements in quality of life, functioning, and symptom burden among patients receiving accelerated treatment. By six weeks, quality-of-life scores improved by approximately 32 percentage points from baseline. The proportion of patients reporting severe functional impairment declined from 85–100% at baseline to 15–17% at the end of treatment, and approximately 60% reached normal-range functioning by the end of treatment. Patients receiving SWIFT also reported earlier perceived symptom improvement across a range of symptoms, consistent with clinician-rated findings.
For more information, visit BrainsWay.com.
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS.
Source: BrainsWay
